In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nivalis Therapeutics Inc.

Division of Alpine Immune Sciences Inc.
www.nivalis.com

Latest From Nivalis Therapeutics Inc.

Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown

Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.

Financing Business Strategies

Start-Up Quarterly Statistics: Private And Public Firms Were Prolific Fundraisers

A review of biopharma start-up dealmaking and financing activity from April through June 2017, based on data from Strategic Transactions, showed that fundraising activity more than doubled compared with the first quarter.

StartUps and SMEs Financing

Deals Shaping The Medical Industry, May 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Deal-making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2017.

Deals BioPharmaceutical

Immune-Focused Discovery Firm Alpine Goes Public With Nivalis Merger

Mitchell Gold, who once led Dendreon, will lead the company, which obtains $90m in funding to bring forward three potential drug candidates for inflammatory conditions and cancer.

Cancer Inflammation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • N30 Pharmaceuticals LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alpine Immune Sciences Inc.
  • Senior Management
  • R. Michael Carruthers, Interim Pres. & CFO
    Janice Troha, COO
  • Contact Info
  • Nivalis Therapeutics Inc.
    Phone: (720) 945-7700
    3122 Sterling Cir.
    Boulder, CO 80301
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register